Last reviewed · How we verify
start cozaar
Cozaar (losartan) blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.
Losartan, an angiotensin II receptor blocker (ARB), is primarily used to treat hypertension and heart failure. It has shown promise in reducing fibrosis and improving outcomes in various conditions, including pancreatic cancer and osteoarthritis. Despite no FDA label for Cozaar, it is widely prescribed off-label for its anti-fibrotic properties.
At a glance
| Generic name | start cozaar |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Angiotensin II receptor antagonist (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the AT1 receptor subtype. By preventing angiotensin II from binding to these receptors, it prevents vasoconstriction and aldosterone secretion, leading to reduced peripheral vascular resistance and lower blood pressure. This mechanism also provides renal protection and reduces left ventricular hypertrophy.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- start cozaar CI brief — competitive landscape report
- start cozaar updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI